Evolocumab reduced cardiovascular risk in kidney disease
Over a median 4.6 years, evolocumab reduced the combined relative risk of coronary heart disease death, heart attack or stroke from a blocked artery by 39% versus placebo.
Our read
Interventions- Studied:
- Randomized trial in 2,140 patients with chronic kidney disease, median 4.6 years (Placebo-controlled)
- What changed:
- Combined risk of coronary heart disease death, heart attack, or ischemic stroke fell 39% with evolocumab versus placebo
- The catch:
- The abstract gives no adverse-event results to weigh against cardiovascular benefits
- In the record:
- The 33rd paper on evolocumab with results in people; 73 on record in all. Its result on LDL cholesterol agrees with all 10 other findings on record.
- Why it’s aging research:
- It bears on staying healthy in midlife and later life.
Editor of record: Boris Djordjevic · AgingResearch.News
Among 12,257 people in a randomized trial, 2,140 had chronic kidney disease and formed a prespecified analysis group. Their median age was 69, and 55% were women. Participants had artery plaque buildup or high-risk diabetes, LDL (“bad”) cholesterol of at least 90 mg/dL, and no previous heart attack or stroke. They received evolocumab or placebo alongside optimized cholesterol-lowering therapy.
After a median 4.6 years, evolocumab reduced the combined risk of coronary heart disease death, heart attack or stroke from a blocked artery. At five years, the absolute reduction in this combined risk was 4.0 percentage points versus placebo. Estimated five-year rates of death from any cause were 12.0% with evolocumab and 16.7% with placebo in the kidney-disease group.
Why it matters
People with chronic kidney disease face a high risk of cardiovascular disease as they age. The findings support intensive cholesterol lowering to prevent first cardiovascular events in this high-risk group.
Caveats
The results came from a prespecified subgroup analysis; the conference abstract did not give the drug dose or adverse-event results. The findings do not cover people with a previous heart attack or stroke.
Evolocumab is part of Bryan Johnson's Blueprint
The paper
Evolocumab in Patients with Chronic Kidney Disease and Without a Prior MI or Stroke in VESALIUS-CV
Radboudumc; Brigham and Women's Hosp
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 14174
Comments
Be the first to comment.